Neutralizing Antibody Responses in COVID-19 Convalescent Sera

2020_-_lee_et_al._-_neutralizing_antibody_responses_in_covid-19_convalescent_sera
William T Lee, Roxanne C Girardin, Alan P Dupuis, II, Karen E Kulas, Anne F Payne, Susan J Wong, Suzanne A. Arinsburg, Freddy T. Nguyen, Damodara Rao Mendu, Adolfo Firpo-Betancourt, Jeffrey S. Jhang, Ania Wajnberg, Florian Krammer, Carlos Cordon-Cardo, Sherlita Amler, Marisa Montecalvo, Brad Hutton, Jill Taylor, Kathleen A McDonough. The Journal of Infectious Diseases 2020-10-26

Full Text
Passive transfer of antibodies from COVID-19 convalescent patients is being used as an experimental treatment for eligible patients with SARS-CoV-2 infections. The United States Food and Drug Administration’s (FDA) guidelines for convalescent plasma initially recommended target antibody titers of 160. We evaluated SARS-CoV-2 neutralizing antibodies in sera from recovered COVID-19 patients using plaque reduction neutralization tests (PRNT) at moderate (PRNT50) and high (PRNT90) stringency thresholds. We found that neutralizing activity significantly increased with time post symptom onset (PSO), reaching a peak at 31–35 days PSO. At this point, the number of sera having neutralizing titers of at least 160 was approximately 93% (PRNT50) and approximately 54% (PRNT90). Sera with high SARS-CoV-2 antibody levels (>960 enzyme-linked immunosorbent assay titers) showed maximal activity, but not all high-titer sera contained neutralizing antibody at FDA recommended levels, particularly at high stringency. These results underscore the value of serum characterization for neutralization activity.
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest
Share on email
Email

Related Posts